These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23476969)

  • 1. Algeta and Ablynx collaborate to discover and develop targeted cancer therapies.
    King G
    Future Med Chem; 2013 Feb; 5(2):123. PubMed ID: 23476969
    [No Abstract]   [Full Text] [Related]  

  • 2. Grants4Targets: an open innovation initiative to foster drug discovery collaborations.
    Dorsch H; Jurock AE; Schoepe S; Lessl M; Asadullah K
    Nat Rev Drug Discov; 2015 Jan; 14(1):74-6. PubMed ID: 25430867
    [No Abstract]   [Full Text] [Related]  

  • 3. Academia-industry alliance: Belfer Institute and sanofi-aventis collaborate to develop new cancer therapeutics.
    Dis Model Mech; 2010; 3(11-12):669. PubMed ID: 21030419
    [No Abstract]   [Full Text] [Related]  

  • 4. The long march of antisense.
    Jones D
    Nat Rev Drug Discov; 2011 Jun; 10(6):401-2. PubMed ID: 21629279
    [No Abstract]   [Full Text] [Related]  

  • 5. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
    Vallance P; Williams P; Dollery C
    Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
    [No Abstract]   [Full Text] [Related]  

  • 6. Deal watch: MSD buys in to emerging epigenetic cancer target.
    Cully M
    Nat Rev Drug Discov; 2016 Mar; 15(3):153. PubMed ID: 26931086
    [No Abstract]   [Full Text] [Related]  

  • 7. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.
    Lee JA; Uhlik MT; Moxham CM; Tomandl D; Sall DJ
    J Med Chem; 2012 May; 55(10):4527-38. PubMed ID: 22409666
    [No Abstract]   [Full Text] [Related]  

  • 8. An accelerated pathway for targeted cancer therapies.
    McClellan M; Benner J; Schilsky R; Epstein D; Woosley R; Friend S; Sidransky D; Geoghegan C; Kessler D
    Nat Rev Drug Discov; 2011 Feb; 10(2):79-80. PubMed ID: 21283090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomedicine. Pharma firms push for sharing of cancer trial data.
    Bhattacharjee Y
    Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer nanotechnology: small, but heading for the big time.
    Nat Rev Drug Discov; 2007 Mar; 6(3):174-5. PubMed ID: 17396287
    [No Abstract]   [Full Text] [Related]  

  • 11. Jay Bradner.
    Nat Rev Drug Discov; 2017 Mar; 16(4):232-233. PubMed ID: 28356589
    [No Abstract]   [Full Text] [Related]  

  • 12. Are the large pharmaceutical and biotechnology companies driving the discovery, research and development of targeted cancer therapies?
    Gallant GJ
    Future Med Chem; 2012 Jan; 4(1):13-7. PubMed ID: 22168161
    [No Abstract]   [Full Text] [Related]  

  • 13. Trial watch: Opportunities and challenges of the 2016 target landscape.
    Lafferty-Whyte K; Mormeneo D; Del Fresno Marimon M
    Nat Rev Drug Discov; 2017 Jan; 16(1):10-11. PubMed ID: 27980340
    [No Abstract]   [Full Text] [Related]  

  • 14. [Forefront of Cancer Targeting Therapy].
    Utoguchi N; Taira Y
    Yakugaku Zasshi; 2018; 138(7):901-902. PubMed ID: 29962466
    [No Abstract]   [Full Text] [Related]  

  • 15. Open innovation: share or die..
    Talaga P
    Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629
    [No Abstract]   [Full Text] [Related]  

  • 16. Scientists Journey Into Genomes Via CRISPR-Cas9.
    Ricks D
    J Natl Cancer Inst; 2015 Nov; 107(11):djv352. PubMed ID: 26538621
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceutical pipeline.
    Lowen T
    Minn Med; 2011 Oct; 94(10):16-8. PubMed ID: 23256279
    [No Abstract]   [Full Text] [Related]  

  • 18. Restructurally sound.
    Borrell B
    Nat Med; 2011 May; 17(5):531-3. PubMed ID: 21546961
    [No Abstract]   [Full Text] [Related]  

  • 19. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
    Perakslis ED; Van Dam J; Szalma S
    Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
    [No Abstract]   [Full Text] [Related]  

  • 20. Open partnering of integrated drug discovery: continuing evolution of the pharmaceutical model.
    Hutchins S; Torphy T; Muller C
    Drug Discov Today; 2011 Apr; 16(7-8):281-3. PubMed ID: 21335101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.